Bitte benutzen Sie diese Referenz, um auf diese Ressource zu verweisen:
doi:10.22028/D291-32735
Titel: | Efficacy and Toxicity of Different Chemotherapy Protocols for Concurrent Chemoradiation in Non-Small Cell Lung Cancer—A Secondary Analysis of the PET Plan Trial |
VerfasserIn: | Gkika, Eleni Lenz, Stefan Schimek-Jasch, Tanja Waller, Cornelius F. Kremp, Stephanie Schaefer-Schuler, Andrea Mix, Michael Küsters, Andreas Tosch, Marco Hehr, Thomas Eschmann, Susanne Martina Bultel, Yves-Pierre Hass, Peter Fleckenstein, Jochen Thieme, Alexander Henry Stockinger, Marcus Dieckmann, Karin Miederer, Matthias Holl, Gabriele Rischke, Hans Christian Adebahr, Sonja König, Jochem Binder, Harald Grosu, Anca-Ligia Nestle, Ursula |
Sprache: | Englisch |
Titel: | Cancers |
Bandnummer: | 12 |
Heft: | 11 |
Verlag/Plattform: | MDPI |
Erscheinungsjahr: | 2020 |
Freie Schlagwörter: | non-small cell lung cancer NSCLC concomitant chemoradiation chemoradiotherapy |
DDC-Sachgruppe: | 610 Medizin, Gesundheit |
Dokumenttyp: | Journalartikel / Zeitschriftenartikel |
Abstract: | (1) Background: The optimal chemotherapy (CHT) regimen for concurrent chemoradiation (cCRT) is not well defined. In this secondary analysis of the international randomized PET-Plan trial, we evaluate the efficacy of different CHT. (2) Methods: Patients with inoperable NSCLC were randomized at a 1:1 ratio regarding the target volume definition and received isotoxically dose-escalated cCRT using cisplatin 80 mg/m2 (day 1, 22) and vinorelbin 15 mg/m2 (day 1, 8, 22, 29) (P1) or cisplatin 20 mg/m2 (day 1–5, 29–33) and vinorelbin 12.5 mg/m2 (day 1, 8, 15, 29, 36, 43) (P2) or carboplatin AUC1 (day 1–5, 29–33) and vinorelbin 12.5 mg/m2 (day 1, 8, 15, 29, 36, 43) (P3) or other CHT at the treating physician’s discretion. (3) Results: Between 05/2009 and 11/2016, 205 patients were randomized and 172 included in the per-protocol analysis. Patients treated in P1 or P2 had a better overall survival (OS) compared to P3 (p = 0.015, p = 0.01, respectively). Patients treated with carboplatin had a worse OS compared to cisplatin (HR 1.78, p = 0.03), but the difference did not remain significant after adjusting for age, ECOG, cardiac function creatinine and completeness of CHT. (4) Conclusions: Carboplatin doublets show no significant difference compared to cisplatin, after adjusting for possibly relevant factors, probably due to existing selection bias. |
DOI der Erstveröffentlichung: | 10.3390/cancers12113359 |
Link zu diesem Datensatz: | urn:nbn:de:bsz:291--ds-327354 hdl:20.500.11880/30122 http://dx.doi.org/10.22028/D291-32735 |
ISSN: | 2072-6694 |
Datum des Eintrags: | 2-Dez-2020 |
Fakultät: | M - Medizinische Fakultät |
Fachrichtung: | M - Radiologie |
Professur: | M - Keiner Professur zugeordnet |
Sammlung: | SciDok - Der Wissenschaftsserver der Universität des Saarlandes |
Dateien zu diesem Datensatz:
Datei | Beschreibung | Größe | Format | |
---|---|---|---|---|
cancers-12-03359.pdf | 822,69 kB | Adobe PDF | Öffnen/Anzeigen |
Diese Ressource wurde unter folgender Copyright-Bestimmung veröffentlicht: Lizenz von Creative Commons